Association of Non-Invasive Markers with Significant Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study

References

• Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009–2019. J Hepatol. 2021;75(4):795–809. doi:10.1016/j.jhep.2021.05.022
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021;22(21):11629. doi:10.3390/ijms222111629
   PubMed Web of Science ®Google Scholar
• Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin Gastroenterol Hepatol. 2022;20(2):283–292 e10. doi:10.1016/j.cgh.2021.05.002
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Nogami A, Yoneda M, Iwaki M, et al. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD. Sci Rep. 2022;12(1):21925. doi:10.1038/s41598-022-25843-6
   PubMed Web of Science ®Google Scholar
• Tao H, Yang JJ, Shi KH, et al. The significance of YKL-40 protein in liver fibrosis. Inflammat Res. 2014;63(4):249–254. doi:10.1007/s00011-013-0698-9
   PubMed Web of Science ®Google Scholar
• Jin X, Fu B, Wu ZJ, et al. Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China. Hepatobil Pancr Dis Int. 2020;19(4):384–389. doi:10.1016/j.hbpd.2020.05.009
   PubMed Web of Science ®Google Scholar
• Jiang Z, Wang S, Jin J, et al. The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases. J Clin Lab Anal. 2020;34(5):e23200. doi:10.1002/jcla.23200
   PubMed Web of Science ®Google Scholar
• Kang Q, Chen J, Luo H, et al. Decrease in chitinase 3-like protein 1 levels reflects improvement in liver fibrosis after HCV eradication. Dis Markers. 2020;2020:8539804. doi:10.1155/2020/8539804
   PubMed Web of Science ®Google Scholar
• Kumagai E, Mano Y, Yoshio S, et al. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6(1):35282. doi:10.1038/srep35282
   PubMedGoogle Scholar
• Li H, Yan T, Zhu Z, et al. [Diagnostic value of serum chitinase 3-like protein 1 in chronic liver disease of significant fibrosis and cirrhosis]. Chin J Hepatol. 2018;26(5):337–341. Chinese. doi:10.3760/cma.j.issn.1007-3418.2018.05.005
   PubMedGoogle Scholar
• Fargion S, Valenti L, Fracanzani AL. Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Digest Liver Dis. 2011;43(2):89–95. doi:10.1016/j.dld.2010.07.006
   Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi:10.1002/hep.20701
   PubMed Web of Science ®Google Scholar
• Stal P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol. 2015;21(39):11077–11087. doi:10.3748/wjg.v21.i39.11077
   PubMed Web of Science ®Google Scholar
• Kugelmas M, Noureddin M, Gunn N, et al. The use of current knowledge and non-invasive testing modalities for predicting at-risk nonalcoholic steatohepatitis and assessing fibrosis. Liver Int. 2023;43(5):964–974. doi:10.1111/liv.15555
   PubMed Web of Science ®Google Scholar
• Cao Y, Guo S, Dong Y, Liu C, Zhu W. Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction. ESC Heart Fail. 2023;10(3):1771–1780. doi:10.1002/ehf2.14336
   PubMed Web of Science ®Google Scholar
• Salomone F, Micek A, Godos J. Simple scores of fibrosis and mortality in patients with NAFLD: a systematic review with meta-analysis. J Clin Med. 2018;7(8):219. doi:10.3390/jcm7080219
   PubMed Web of Science ®Google Scholar
• Xia F, Huang Z, Zhang Q, et al. Clinically significant portal hypertension (CSPH) on early-stage HCC following hepatectomy: what’s the impact? Eur J Surg Oncol. 2023;49(4):771–779. doi:10.1016/j.ejso.2022.11.005
   PubMed Web of Science ®Google Scholar
• Nishimura N, De Battista D, McGivern DR, et al. Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proc Natl Acad Sci U S A. 2021;118(17). doi:10.1073/pnas.2019633118
   Web of Science ®Google Scholar
• Zhang S, Sousa A, Lin M, et al. Role of chitinase 3-like 1 protein in the pathogenesis of hepatic insulin resistance in nonalcoholic fatty liver disease. Cells. 2021;10(2). doi:10.3390/cells10020201
   Web of Science ®Google Scholar
• Fontana RJ, Litman HJ, Dienstag JL, et al. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int. 2012;32(4):665–674. doi:10.1111/j.1478-3231.2011.02686.x
   PubMed Web of Science ®Google Scholar
• Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 like-protein-1 function and its role in diseases. Sig Transd Target Therapy. 2020;5(1):201. doi:10.1038/s41392-020-00303-7
   PubMed Web of Science ®Google Scholar
• Pungpapong S, Nunes DP, Krishna M, et al. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transplant. 2008;14(9):1294–1302. doi:10.1002/lt.21508
   PubMed Web of Science ®Google Scholar
• Higashiyama M, Tomita K, Sugihara N, et al. Chitinase 3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis. Hepatol Res. 2019;49(11):1316–1328. doi:10.1111/hepr.13396
   PubMed Web of Science ®Google Scholar
• He CH, Lee CG, Ma B, Kamle S, Choi AMK, Elias JA. N-glycosylation regulates chitinase 3-like-1 and IL-13 ligand binding to IL-13 receptor α2. Am J Respir Cell Mol Biol. 2020;63(3):386–395. doi:10.1165/rcmb.2019-0446OC
   PubMed Web of Science ®Google Scholar
• He CH, Lee CG, Dela Cruz CS, et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor alpha2. Cell Rep. 2013;4(4):830–841. doi:10.1016/j.celrep.2013.07.032
   PubMed Web of Science ®Google Scholar
• Lebensztejn DM, Wierzbicka A, Socha P, et al. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta biochimica Polonica. 2011;58(4):563–566. doi:10.18388/abp.2011_2225
   PubMed Web of Science ®Google Scholar
• European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–264. doi:10.1016/j.jhep.2015.04.006
   PubMed Web of Science ®Google Scholar
• Johannessen A, Stockdale AJ, Henrion MYR, et al. Systematic review and individual-patient-data meta-analysis of non-invasive fibrosis markers for chronic hepatitis B in Africa. Nat Commun. 2023;14(1):45. doi:10.1038/s41467-022-35729-w
   PubMed Web of Science ®Google Scholar
• Cazac GD, Lacatusu CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM. Ultrasound-based hepatic elastography in non-alcoholic fatty liver disease: focus on patients with type 2 diabetes. Biomedicines. 2022;10(10):2375. doi:10.3390/biomedicines10102375
   PubMed Web of Science ®Google Scholar
• Ferraioli G, Wong VW, Castera L, et al. Liver ultrasound elastography: an update to the world federation for ultrasound in medicine and biology guidelines and recommendations. Ultrasound Med Biol. 2018;44(12):2419–2440. doi:10.1016/j.ultrasmedbio.2018.07.008
   PubMed Web of Science ®Google Scholar
• Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2021;75(4):770–785. doi:10.1016/j.jhep.2021.04.044
   PubMed Web of Science ®Google Scholar
• Adams LA, George J, Bugianesi E, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26(10):1536–1543. doi:10.1111/j.1440-1746.2011.06774.x
   PubMed Web of Science ®Google Scholar
• Jézéquel C, Lainé F, Laviolle B, Kiani A, Bardou-Jacquet E, Deugnier Y. Both hepatic and body iron stores are increased in dysmetabolic iron overload syndrome. A case-control study. PLoS One. 2015;10(6):e0128530. doi:10.1371/journal.pone.0128530
   PubMed Web of Science ®Google Scholar
• Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol. 2003;38(1):32–38. doi:10.1016/s0168-8278(02)00331-8
   PubMed Web of Science ®Google Scholar
• Manousou P, Kalambokis G, Grillo F, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int. 2011;31(5):730–739. doi:10.1111/j.1478-3231.2011.02488.x
   PubMed Web of Science ®Google Scholar
• Seyedian SS, Hajiani E, Hashemi SJ, et al. Relationship between serum ferritin level and transient elastography findings among patients with nonalcoholic fatty liver disease. J Fam Med Primary Care. 2017;6(4):750–754. doi:10.4103/jfmpc.jfmpc_158_17
   PubMedGoogle Scholar
• Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76(1):99–128. doi:10.1007/s00018-018-2947-0
   PubMed Web of Science ®Google Scholar
• Corradini E, Buzzetti E, Dongiovanni P, et al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol. 2021;75(3):506–513. doi:10.1016/j.jhep.2021.03.014
   PubMed Web of Science ®Google Scholar
• Modares Mousavi SR, Geramizadeh B, Anushiravani A, Ejtehadi F, Anbardar MH, Moini M. Correlation between serum ferritin level and histopathological disease severity in non-alcoholic fatty liver disease. Middle East J Digest Dis. 2018;10(2):90–95. doi:10.15171/mejdd.2018.96
   PubMedGoogle Scholar